Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.
A strain of bird flu that scientists thought could not infect people has shown up in a Taiwanese...
Shares of ImmunoGen jumped 13 percent Monday after Novartis licensed another of its potential...
The Shiga University of Medical Science has become the third Japanese institution to conclude that a clinical study report on Novartis Pharma K.K.'s Diovan blood pressure-lowering drug contained doubtful data and was inappropriate, largely because a Novartis employee participated in the study.
Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan even though it said negative currency trends contributed to a 6 percent drop in its third-quarter net profit.
A health ministry panel on Monday questioned Novartis Pharma K.K.'s use of clinical research data in promoting the sale of its blood pressure-lowering drug Diovan, saying it "could constitute misleading advertisement" following the revelation that some of the data was manipulated.
The FDA granted breakthrough therapy designation to Novartis' experimental drug bimagrumab, also known as BYM338, for sporadic inclusion body myositis (sIBM), the company reported Tuesday. Timothy Wright, global head of development at Novartis Pharmaceuticals, remarked "with no effective therapies currently available for sIBM, bimagrumab has the potential to be the first real option for patients with this condition."
Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.
The Jikei University School of Medicine on Tuesday became the second Japanese university to find that clinical data had been manipulated for Novartis Pharma K.K.'s Diovan blood pressure lowering drug. The university's guest professor Seibu Mochizuki, who led its research on the drug, offered his plan to withdraw his paper on the drug carried by the British Lancet medical journal in 2007.
A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex (TSC) - a genetic disease characterized by benign tumors on multiple organ systems.
Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter. The Basel-based company said it expects full-year sales to grow at a rate in the low single-digits, boosted by delays in generic...
Data employed in a clinical study on Novartis Pharma K.K.'s blockbuster blood pressure lowering drug Diovan were found to be manipulated, the Kyoto Prefectural University of Medicine announced Thursday. The research based on around 3,000 Japanese with high blood pressure was started in 2004 by Hiroaki Matsubara, a former professor at the university, who released papers between 2008 and 2012.
Novartis AG said Friday its drug serelaxin, a treatment for acute heart failure, received breakthrough therapy status from the Food and Drug Administration. The drug is intended to treat symptoms of acute heart failure episodes. Novartis said there are about 3.5 million of those in the U.S. and...
Questcor Pharmaceuticals Inc. said Tuesday it will pay at least $135 million to buy an autoimmune and inflammatory disease drug made by Novartis AG, sending its shares surging in morning trading. Questcor said it will pay $60 million upfront for Synacthen and Synacthen Depot.
A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.
Atlas Venture has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Oxford BioMedica, the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months.
Concerned about the skyrocketing cost of cancer treatment, cancer specialists are demanding that drug companies roll back their prices on cancer treatments. In a scathing report doctors are saying that the costs of cancer drugs are unsustainable and harming patients.
The U.S. government sued Novartis Pharmaceuticals Corp. again on Friday, saying it paid kickbacks for a decade to doctors to steer patients toward its drugs, sometimes disguising fishing trips off the Florida coast and trips to Hooters restaurants as speaking engagements for the doctors.
Novartis plans to trim production and cut about 300 jobs from its Lincoln, Neb. payroll. The Swiss pharmaceutical company said Wednesday that the job cuts will occur over the next two years, leaving about 450 workers to concentrate on making three products: Excedrin, Theraflu and a veterinary medication, Sentinel.
Swiss pharmaceutical company Novartis AG has reported a 6.7 percent increase in profit for the first quarter, boosted by new products and emerging markets. Novartis says its net profit rose to $2.42 billion from $2.27 billion in the same period last year. The Basel-based company said in a...
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. The ruling, which was handed down on Monday, signals the latest shift in the world of drug development in emerging markets...
India's Supreme Court on Monday rejected drug maker Novartis AG's right to patent a new version of a cancer drug in a landmark decision that healthcare activists say ensures the poor will get continued access to cheap, generic versions of lifesaving medicines. Novartis had argued that it needed...
Novartis announced that the FDA approved TOBI Podhaler, an inhaled powder formulation of tobramycin, for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa bacteria in the lungs. Edward Cox noted that the "product is the first dry powder antibacterial drug delivered with a handheld dry powder inhaler."
Novartis AG said Friday that its experimental cancer drug LDK378 was designated as a breakthrough therapy by the Food and Drug Administration. The Swiss drugmaker is studying LDK378 as a treatment for a rare type of metastatic non-small cell lung cancer. It is intended for patients whose cancer...
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Orexo AB today announced that Novartis AG has sent a notice of termination of the license agreement dated August 27, 2009. The OX17 program was aimed for the treatment of gastroesophageal reflux disease (GERD) and is still in early clinical phase.
- Page 1